Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment

•Hemoglobin A1c (HbA1c) declined after initiating elexacaftor/tezacaftor/ivacaftor.•HbA1c declined irrespective of age, sex, and baseline glucose tolerance status.•Insulin use was unchanged after initiation with elexacaftor/tezacaftor/ivacaftor.•In those with diabetes, continuous glucose monitoring measures were also unaltered.